Dyslipidemia: When Statins Aren’t Enough– Review the epidemiology and burden of disease related to cardiovascular risk in patients with primary hyperlipidemia and familial hypercholesterolemia (FH) who are not achieving optimal LDL cholesterol target goals with or without statin-based management.
Review the emerging data on new mechanisms for LDL-lowering, including MTP inhibitors, Apo-B inhibition, CETP inhibitors, and PCSK 9 inhibitors to achieve LDL-C target goals for high patients with dyslipidemia.
Review the underlying genetic mutations and the role of genetic screening for HeFH and HoFH as it relates to diagnosis and treatment of familial hypercholesterolemia and in response to statins, ezetimibe and proprotein convertase subtilisin kexin 9 (PCSK9) monoclonal antibody treatment.
Discuss the emerging evidence on genetic mutations and their potential therapeutic significance in the development of novel LDL targets.
Identify the relationship of LDL-C reduction and CVD risk reduction including the risk in HeFH and HoFH.
Discuss the clinical presentation and implications of heterozygous familial hypercholesterolemia (HeFH) and the use of optimal LDL-C target goals for these patients based on current consensus recommendations.
1.0 Free CEUs for Nurses
This course also offers Free CME for Physicians and Nurse Practitioners